Renalytix to Present at 42nd Annual William Blair Growth Stock Conference

June 8, 2022

NEW YORK and SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at

For further information, please contact:

James McCullough, CEOVia Walbrook PR 
Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600 
Alex Price / Nicholas Moore  
Investec Bank plc (Joint Broker)Tel: 020 7597 4000 
Gary Clarence / Daniel Adams  
Walbrook PR Limited Tel: 020 7933 8780 or 
Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 
CapComm PartnersTel: 415-389-6400 or 
Peter DeNardo   

About Renalytix 
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosisTM for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit